Pomelo Care Raises $92 Million Series C to Expand Virtual Maternity and Women’s Health Platform

Pomelo Care has closed a $92 million Series C financing round, bringing the company to a reported valuation of $1.7 billion and positioning it for broader expansion across women’s health. The funding will support Pomelo’s transition from a maternity-focused virtual care provider into a multi-stage platform spanning pregnancy, pediatrics, and midlife care, with services now covering more than 25 million lives across the United States.

The company has differentiated itself by emphasizing measurable, claims-based outcomes at a time when many digital health models face skepticism around engagement and real-world impact. Pomelo’s care delivery approach is built around a clinician-led virtual model supported by workflow-integrated clinical decision tools, rather than consumer-facing engagement features alone. According to the company, this model has demonstrated reductions in both clinical risk and healthcare utilization.

Pomelo reports that its virtual maternity program has reduced preterm births by 37% and emergency room visits by 46%. Additional outcomes data show a 6.8-day reduction in neonatal intensive care unit length of stay for infants, alongside prenatal depression screening and follow-up rates that are 718% higher than the national average. From a financial perspective, the company states that its programs deliver a 3x to 5x return on investment for payers and employers by addressing high-cost drivers such as preterm delivery and avoidable emergency care.

With the new capital, Pomelo is expanding beyond maternity into pediatric care and launching a Midlife Care Program focused on perimenopause and menopause. The midlife offering targets hormonal and metabolic changes that are often underdiagnosed or undertreated within traditional care models. Early program data indicate that within 60 days of enrollment, patients reported an 88% reduction in symptoms, while 73% noted increased workplace productivity after starting care.

The funding round included backing from investors such as Stripes, Andreessen Horowitz, and Atomico, reinforcing Pomelo’s positioning as a long-term infrastructure partner for women’s health rather than a point solution. As payers including UnitedHealthcare and Aetna increasingly require demonstrable value-based outcomes, Pomelo’s peer-reviewed and claims-validated results may provide a competitive advantage in contracting and expansion discussions.

By extending its virtual care model across multiple life stages, Pomelo is seeking to address persistent gaps in access and continuity while aligning clinical outcomes with financial sustainability for employers and health plans.

Click here for the original news story.